Xeris Pharmaceuticals (XERS) PT Lowered to $9 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts XERS Hot Sheet
Price: $10.59 +2.32%
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Jefferies analyst David Steinberg lowered the price target on Xeris Pharmaceuticals (NASDAQ: XERS) to $9.00 (from $11.00) while maintaining a Buy rating.
You May Also Be Interested In
- Xeris Biopharma adds Menassie Taddese to its board
- Sportradar Group AG (SRAD) PT Raised to $16 at StoneX
- Sprout Social Inc. (SPT) PT Raised to $15 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
